Pfizer administers COVID-19 vaccines to infants, kids in new trial
Fox News
The first participants aged six months to 11 years have been administered Pfizer’s COVID-19 vaccine as part of a global trial assessing safety and tolerability in younger age groups, the company announced Thursday.
The initial phase of the trial will determine the right dose levels from 10, 20 to 30 micrograms, across three age groups; 5 to 11 years, 2 to 5 years and six months to 2 years among 144 kids total. The vaccine is currently authorized for use in people aged 16 and older, administered in two-30 microgram doses spaced 21 days apart. The company will first test the lowest dose (10 µg) in the oldest group (5-11 years), and then proceed to higher doses, while starting to administer shots in the younger age groups with the lowest doses. Later phases in the trial will examine factors like safety and tolerability of the chosen dose for each group against a placebo arm.More Related News
Clonazepam, popular anxiety-reducing drug, recalled nationwide for ‘possibly life-threatening’ error
The anxiety-reducing drug, Clonazepam, has been recalled after a potentially "life-threatening" label mix-up, the FDA said in the recall.